Approach to Prostate Cancer Treatment in Elderly Patients with High Comorbidity

TAVUKÇU, HASAN HÜSEYİN; Kaplan, Mustafa

doi:10.4274/uob.galenos.2019.1455

Approach to Prostate Cancer Treatment in Elderly Patients with High Comorbidity

Hasan Hüseyin TAVUKÇU, (Türkiye Sağlık Bilimleri Üniversitesi Sultan 2. Abdülhamid Han Eğitim ve Araştırma Hastanesi, Üroloji Kliniği, İstanbul, Türkiye)

Mustafa KAPLAN (Vega Hastanesi, Üroloji Kliniği, Tekirdağ, Türkiye)

Üroonkoloji Bülteni

2 0

Yıl: 2021 Cilt: 20 Sayı: 2 Sayfa Aralığı: 73 - 82 Metin Dili: İngilizce DOI: 10.4274/uob.galenos.2019.1455 İndeks Tarihi: 20-05-2022

Approach to Prostate Cancer Treatment in Elderly Patients with High Comorbidity

Öz:

The incidence of prostate cancer increases with age, and elderly patients often have other accompanying diseases. The most important clinical prediction for deciding on curative treatment in localized prostate cancer treatment is the 10-year survival status of the patient. In advanced prostate cancers, treatment is usually decided according to the comorbidity and age of the patients. Guidelines and consensus reports recommend that patients’ general health status should be determined by validated health status screening forms in deciding on treatment for prostate cancer in elderly patients. After evaluating the health status, the treatment options recommended by the guidelines should be presented to the patients according to the risk group of the patient and the treatability of the existing diseases, regardless of their age. Patients who are found to be healthy as a result of the evaluation should be included in the standard treatment applied to non-elderly patients. For patients who are frail but have treatable disease, standard treatment is recommended after correction or improvement of comorbidities. Supportive treatment and adapted treatment options should be offered to the patients who are in a frail state.

Anahtar Kelime:

Yaşlılarda Prostat Kanseri Tedavisine Yaklaşım Yüksek Komorbiditesi Olan Hastalar

Öz:

Prostat kanseri insidansı yaşla birlikte artar ve yaşlı hastalarda sıklıkla eşlik eden başka hastalıklar bulunur. için en önemli klinik tahmin Lokalize prostat kanseri tedavisinde küratif tedaviye karar vermek hastanın 10 yıllık sağkalım durumudur. İlerlemiş prostat kanserlerinde tedavi genellikle hastaların komorbiditesine ve yaşına göre karar verilir. Kılavuzlar ve fikir birliği raporları, hastaların genel sağlık durumunun yaşlı hastalarda prostat kanseri tedavisine karar verirken geçerli sağlık durumu tarama formları ile belirlenmelidir. Sağlık durumunu değerlendirdikten sonra, Hastanın risk grubuna ve tedavi edilebilirliğine göre kılavuzların önerdiği tedavi seçenekleri hastalara sunulmalıdır. Yaşlarına bakılmaksızın mevcut hastalıklar. Değerlendirme sonucunda sağlıklı bulunan hastalar uygulanan standart tedaviye dahil edilmelidir. yaşlı olmayan hastalar. Kırılgan ancak tedavi edilebilir hastalığı olan hastalar için, komorbiditelerin düzeltilmesi veya iyileştirilmesinden sonra standart tedavi önerilir. Kırılgan durumdaki hastalara destekleyici tedavi ve uyarlanmış tedavi seçenekleri sunulmalıdır.

Anahtar Kelime:

Belge Türü: Makale Makale Türü: Derleme Erişim Türü: Erişime Açık

1. National Cancer Institute. SEERCancer Stat Facts: prostate cancer. 2018. Available from: https//seercancergouv/statfacts/html/ prosthtml2018. 2018.
2. Smith BD, Smith GL, Hurria A, et al. Future of cancer incidence in the United States: burdens upon an aging, changing nation. J Clin Oncol 2009;27:2758-2765.
3. Arnold M, Karim-Kos HE, Coebergh JW, et al. Recent trends in incidence of five common cancers in 26 European countries since 1988: analysis of the European Cancer Observatory. Eur J Cancer 2015;51:1164-1187.
4. Boyle HJ, Alibhai S, Decoster L, et al. Updated recommendations of the International Society of Geriatric Oncology on prostate cancer management in older patients. Eur J Cancer 2019;116:116-136.
5. Hamilton AS, Albertsen PC, Johnson TK, et al. Trends in the treatment of localized prostate cancer using supplemented cancer registry data. BJU Int 2011;107:576-584.
6. Albertsen PC, Moore DF, Shih W, et al. Impact of comorbidity on survival among men with localized prostate cancer. J Clin Oncol 2011;29:1335.
7. Droz JP, Balducci L, Bolla M, et al. Background for the proposal of SIOG guidelines for the management of prostate cancer in senior adults. Crit Rev Oncol Hematol 2010;73:68-91.
8. Droz JP, Balducci L, Bolla M, et al. Management of prostate cancer in older men: recommendations of a working group of the International Society of Geriatric Oncology. BJU Int 2010;106:462-469.
9. Droz JP, Albrand G, Gillessen S, et al. Management of prostate cancer in elderly patients: recommendations of a task force of the International Society of Geriatric Oncology. Eur Urol 2017;72:521-531.
10. Droz JP, Aapro M, Balducci L, et al. Management of prostate cancer in older patients: updated recommendations of a working group of the International Society of Geriatric Oncology. Lancet Oncol 2014;15:e404-e414. doi: 10.1016/S1470-2045(14)70018-X.
11. Soubeyran P, Bellera C, Goyard J, et al. Screening for vulnerability in older cancer patients: the ONCODAGE Prospective Multicenter Cohort Study. PLoS One 2014;9:e115060. doi: 10.1371/journal. pone.0115060.
12. Droz JP, Boyle H, Albrand G, et al. Role of geriatric oncologists in optimizing care of urological oncology patients. Eur Urol Focus 2017;3:385-394.
13. Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982;5:649-655.
14. Wedding U, Kodding D, Pientka L, et al. Physicians’ judgement and comprehensive geriatric assessment (CGA) select different patients as fit for chemotherapy. Crit Rev Oncol Hematol 2007;64:1-9.
15. Wildiers H, Heeren P, Puts M, et al. International Society of Geriatric Oncology consensus on geriatric assessment in older patients with cancer. J Clin Oncol 2014;32:2595-2603.
16. Decoster L, Van Puyvelde K, Mohile S, et al. Screening tools for multidimensional health problems warranting a geriatric assessment in older cancer patients: an update on SIOG recommendationsdagger. Ann Oncol 2015;26:288-300.
17. Mottet N BJ, Bolla M, Briers E, et al. EAU e ESTRO e ESUR e SIOG guidelines on prostate cancer. Part 1: screening, diagnosis, and local treatment with curative intent. Eur Urol 2017;71:618-629.
18. Tsoi KK, Chan JY, Hirai HW, et al. Cognitive Tests to Detect Dementia: A Systematic Review and Meta-analysis. JAMA Intern Med 2015;175:1450-1458.
19. Borson S, Scanlan JM, Chen P, Ganguli M. The Mini-Cog as a screen for dementia: validation in a population-based sample. J Am Geriatr Soc 2003;51:1451-1454.
20. Solomon DH. Geriatric assessment: methods for clinical decision making. JAMA 1988;259:2450-2452.
21. Reuben DB, Fishman LK, McNabney M, Wolde-Tsadik G. Looking inside the black box of comprehensive geriatric assessment: a classification system for problems, recommendations, and implementation strategies. J Am Geriatr Soc 1996;44:835-838.
22. Ellis G, Gardner M, Tsiachristas A, et al. Comprehensive geriatric assessment for older adults admitted to hospital. Cochrane Database Syst Rev 2017;9:CD006211. doi: 10.1002/14651858.CD006211. pub3
23. Puts MTE, Sattar S, Kulik M, et al. A randomized phase II trial of geriatric assessment and management for older cancer patients. Support Care Cancer 2018;26:109-117.
24. Schmidt H, Boese S, Lampe K, et al. Trans sectoral care of geriatric cancer patients based on comprehensive geriatric assessment and patient-reported quality of life - Results of a multicenter study to develop and pilot test a patient-centered interdisciplinary care concept for geriatric oncology patients (PIVOG). J Geriatr Oncol 2017;8:262-270.
25. Magnuson A, Lemelman T, Pandya, et al. Geriatric assessment with management intervention in older adults with cancer: a randomized pilot study. Support Care Cancer 2018;26:605-613.
26. NCI clinical trials. 2018. https://ClinicaltrialsGouv/Ct2/ Results?Terms=cancer+and+ geriatric assessment&search.
27. Kalsi T, Babic-Illman G, Ross PJ, et al. The impact of comprehensive geriatric assessment interventions on tolerance to chemotherapy in older people. Br J Cancer 2015;112:1435-1444.
28. McCleary NJ, Wigler D, Berry D, et al. Feasibility of computer-based self-administered cancer-specific geriatric assessment in older patients with gastrointestinal malignancy. Oncologist 2013;18:64-72.
29. Hurria A, Akiba C, Kim J, et al. Reliability, validity, and feasibility of a computer-based geriatric assessment for older adults with cancer. J Oncol Pract 2016;12:e1025-e1034. doi: 10.1200/JOP.2016.013136.
30. Shahrokni A, Tin A, Downey RJ, et al. Electronic Rapid Fitness Assessment: A Novel Tool for Preoperative Evaluation of the Geriatric Oncology Patient. J Natl Compr Canc Netw 2017;15:172-179.
31. Mohile SG, Dale W, Somerfield MR, Hurria A. Practical assessment and management of vulnerabilities in older patients receiving chemotherapy: ASCO guideline for geriatric oncology summary. J Oncol Pract 2018;14:442-446.
32. University of california eprognosis: electronic tools. 2018. https:// EprognosisUcsfEdu/IndexPhp.
33. Liu D, Lehmann HP, Frick KD, Carter HB. Active surveillance versus surgery for low risk prostate cancer: a clinical decision analysis. J Urol 2012;187:1241-1246.
34. Albertsen PC, Hanley JA, Fine J. 20-year outcomes following conservative management of clinically localized prostate cancer. JAMA 2005;293:2095-2101.
35. Hamdy FC, Donovan JL, Lane JA, et al. 10-Year outcomes after monitoring, surgery, or radiotherapy for localized prostate cancer. N Engl J Med 2016;375:1415-1424.
36. Scosyrev E, Messing EM, Mohile S, Golijanin D, Wu G. Prostate cancer in the elderly: frequency of advanced disease at presentation and disease-specific mortality. Cancer 2012;118:3062-3070.
37. Briganti A, Spahn M, Joniau S, et al. Impact of age and comorbidities on long-term survival of patients with high-risk prostate cancer treated with radical prostatectomy: a multi-institutional competingrisks analysis. Eur Urol 2013;63:693-701.
38. Bill-Axelson A, Holmberg L, Garmo H, et al. Radical prostatectomy or watchful waiting in early prostate cancer. N Engl J Med 2014;370:932-942.
39. Joniau S, Briganti A, Gontero P, et al. Stratification of high-risk prostate cancer into prognostic categories: a European multi-institutional study. Eur Urol 2015;67:157-164.
40. Begg CB, Riedel ER, Bach PB, et al. Variations in morbidity after radical prostatectomy. N Engl J Med 2002;346:1138-1144.
41. Stanford JL, Feng Z, Hamilton AS, et al. Urinary and sexual function after radical prostatectomy for clinically localized prostate cancer: the Prostate Cancer Outcomes Study. JAMA 2000;283:354-360.
42. Kundu SD, Roehl KA, Eggener SE, et al. Potency, continence and complications in 3,477 consecutive radical retropubic prostatectomies. J Urol 2004;172:2227-2231.
43. Kupelian PA, Elshaikh M, Reddy CA, et al. Comparison of the efficacy of local therapies for localized prostate cancer in the prostatespecific antigen era: a large single-institution experience with radical prostatectomy and external-beam radiotherapy. J Clin Oncol 2002;20:3376-3385.
44. Dearnaley D, Syndikus I, Mossop H, et al. Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial. Lancet Oncol 2016;17:1047-1060.
45. Incrocci L, Wortel RC, Alemayehu WG, et al. Hypofractionated versus conventionally fractionated radiotherapy for patients with localised prostate cancer (HYPRO): final efficacy results from a randomised, multicentre, open-label, phase 3 trial. Lancet Oncol 2016;17:1061-1069.
46. Arcangeli G, Saracino B, Arcangeli S, et al. Moderate hypofractionation in high-risk, organ-confined prostate cancer: final results of a phase III randomized trial. J Clin Oncol 2017;35:1891-1897.
47. Catton CN, Lukka H, Gu CS, et al. Randomized trial of a hypofractionated radiation regimen for the treatment of localized prostate cancer. J Clin Oncol 2017;35:1884-1890.
48. Lee WR, Dignam JJ, Amin MB, et al. Randomized phase III noninferiority study comparing two radiotherapy fractionation schedules in patients with low-risk prostate cancer. J Clin Oncol 2016;34:2325-2332.
49. Shahid N, Loblaw A, Chung HT, et al. Long-term toxicity and health-related quality of life after single-fraction high dose rate brachytherapy boost and hypofractionated external beam radiotherapy for ıntermediate-risk prostate cancer. Clin Oncol (R Coll Radiol) 2017;29:412-420.
50. Joseph N, Taylor C, O’Hara C, et al. A combined single high-dose rate brachytherapy boost with hypofractionated external beam radiotherapy results in a high rate of biochemical disease free survival in localised intermediate and high risk prostate cancer patients. Radiother Oncol 2016;121:299-303.
51. Morris WJ, Tyldesley S, Rodda S, et al. Androgen Suppression Combined with Elective Nodal and Dose Escalated Radiation Therapy (the ASCENDE-RT Trial): an analysis of survival endpoints for a randomized trial comparing a low-dose-rate brachytherapy boost to a dose-escalated external beam boost for high- and ıntermediate-risk prostate cancer. Int J Radiat Oncol Biol Phys 2017;98:275-285.
52. Rodda S, Tyldesley S, Morris WJ, et al. ASCENDE-RT: an analysis of treatment-related morbidity for a randomized trial comparing a lowdose-rate brachytherapy boost with a dose-escalated external beam boost for high- and ıntermediate-risk prostate cancer. Int J Radiat Oncol Biol Phys 2017;98:286-295.
53. Rodda S, Morris WJ, Hamm J, Duncan G. ASCENDE-RT: an analysis of health-related quality of life for a randomized trial comparing lowdose-rate brachytherapy boost with dose-escalated external beam boost for high- and intermediate-risk prostate cancer. Int J Radiat Oncol Biol Phys 2017;98:581-589.
54. Hoskin P, Rojas A, Ostler P, et al. Single-dose high-dose-rate brachytherapy compared to two and three fractions for locally advanced prostate cancer. Radiother Oncol 2017;124:56-60.
55. D’Amico AV, Chen MH, Renshaw AA, et al. Androgen suppression and radiation vs radiation alone for prostate cancer: a randomized trial. JAMA 2008;299:289-295.
56. Jones CU, Hunt D, McGowan DG, et al. Radiotherapy and short-term androgen deprivation for localized prostate cancer. N Engl J Med 2011;365:107-118.
57. Studer UE, Collette L, Whelan P, et al. Using PSA to guide timing of androgen deprivation in patients with T0–4 N0–2 M0 prostate cancer not suitable for local curative treatment (EORTC 30891). Eur Urol 2008;53:941-949.
58. Studer UE, Whelan P, Albrecht W, et al. Immediate or deferred androgen deprivation for patients with prostate cancer not suitable for local treatment with curative intent: European Organisation for Research and Treatment of Cancer (EORTC) trial 30891. J Clin Oncol 2006;24:1868-1876.
59. Fizazi K, Tran N, Fein L, et al. Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer. N Engl J Med 2017;377:352-360.
60. Chi KN, Protheroe A, Rodriguez-Antolin A, et al. Patient-reported outcomes following abiraterone acetate plus prednisone added to androgen deprivation therapy in patients with newly diagnosed metastatic castration-naive prostate cancer (LATITUDE): an international, randomised phase 3 trial. Lancet Oncol 2018;19:194-206.
61. James ND, de Bono JS, Spears MR, et al. Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy. N Engl J Med 2017;377:338-351.
62. Kyriakopoulos CE, Chen YH, Carducci MA, et al. chemohormonal therapy in metastatic hormone-sensitive prostate cancer: long-term survival analysis of the randomized phase III E3805 CHAARTED trial. J Clin Oncol 2018;36:1080-1087.
63. Gravis G, Boher JM, Joly F, et al. Androgen Deprivation Therapy (ADT) plus docetaxel versus adt alone in metastatic non castrate prostate cancer: impact of metastatic burden and long-term survival analysis of the randomized phase 3 GETUG-AFU15 trial. Eur Urol 2016;70:256-262.
64. James ND, Sydes MR, Clarke NW, et al. Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. Lancet 2016;387:1163-1177.
65. Sweeney CJ, Chen YH, Carducci M, et al. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer. N Engl J Med 2015;373:737-746.
66. Sydes MR, Spears MR, Mason MD, et al. Adding abiraterone or docetaxel to long-term hormone therapy for prostate cancer: directly randomised data from the STAMPEDE multi-arm, multi-stage platform protocol. Ann Oncol 2018;29:1235-1248.
67. Wallis CJD, Klaassen Z, Bhindi B, et al. Comparison of abiraterone acetate and docetaxel with androgen deprivation therapy in highrisk and metastatic hormone-naive prostate cancer: a systematic review and network meta-analysis. Eur Urol 2018;73:834-844.
68. Parker CC, James ND, Brawley CD, et al. Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial. Lancet 2018;392:2353-2366.
69. Italiano A, Ortholan C, Oudard S, et al. Docetaxel-based chemotherapy in elderly patients (age 75 and older) with castrationresistant prostate cancer. Eur Urol 2009;55:1368-1375.
70. Aapro M, Saad F. Bone-modifying agents in the treatment of bone metastases in patients with advanced genitourinary malignancies: a focus on zoledronic acid. Ther Adv Urol 2012;4:85-101.
71. Berthold DR, Pond GR, Soban F, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. J Clin Oncol 2008;26:242-245.
72. Kellokumpu-Lehtinen PL, Harmenberg U, Joensuu T, et al. 2-Weekly versus 3-weekly docetaxel to treat castration-resistant advanced prostate cancer: a randomised, phase 3 trial. Lancet Oncol 2013;14:117-124.
73. Oudard S, Fizazi K, Sengelov L, et al. Cabazitaxel Versus Docetaxel As First-Line Therapy for Patients With Metastatic Castration-Resistant Prostate Cancer: A Randomized Phase III Trial-FIRSTANA. J Clin Oncol 2017;35:3189-3197.
74. Eisenberger M, Hardy-Bessard AC, Kim CS, et al. Phase III study comparing a reduced dose of cabazitaxel (20 mg/m(2)) and the currently approved dose (25 mg/m(2)) in postdocetaxel patients with metastatic castration-resistant prostate cancer-PROSELICA. J Clin Oncol 2017;35:3198-3206.
75. Climent MA, Perez-Valderrama B, Mellado B, et al. Weekly cabazitaxel plus prednisone is effective and less toxic for ‘unfit’ metastatic castration-resistant prostate cancer: Phase II Spanish Oncology Genitourinary Group (SOGUG) trial. Eur J Cancer 2017;87:30-37.
76. Hui MM, Clement CI. Evaluation of the early to mid-term efficacy and safety of deep sclerectomy without an ıntrascleral spacer for open-angle glaucoma in an Australian population. J Curr Glaucoma Pract 2018;12:107-112.
77. Sternberg CN, de Bono JS, Chi KN, et al. Improved outcomes in elderly patients with metastatic castration-resistant prostate cancer treated with the androgen receptor inhibitor enzalutamide: results from the phase III AFFIRM trial. Ann Oncol 2014;25:429-434.
78. De Bono JS, Logothetis CJ, Molina A, et al. Abiraterone and increased survival in metastatic prostate cancer. N Eng J Med 2011;364:1995-2005.
79. Scher HI, Fizazi K, Saad F, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med 2012;367:1187-1197.
80. De Bono JS, Oudard S, Ozguroglu M, et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet 2010;376:1147-1154.
81. Fizazi K, Scher HI, Molina A, et al. Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebocontrolled phase 3 study. Lancet Oncol 2012;13:983-992.
82. Kantoff PW, Higano CS, Shore ND, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010;363:411-422.
83. Bahl A, Oudard S, Tombal B, et al. Impact of cabazitaxel on 2-year survival and palliation of tumour-related pain in men with metastatic castration-resistant prostate cancer treated in the TROPIC trial. Ann Oncol 2013;24:2402-2428.
84. Prior JO, Gillessen S, Wirth M, et al. Radiopharmaceuticals in the elderly cancer patient: Practical considerations, with a focus on prostate cancer therapy: A position paper from the International Society of Geriatric Oncology Task Force. Eur J Cancer 2017;77:127-139.
85. Parker C, Zhan L, Cislo P, et al. Effect of radium-223 dichloride (Ra223) on hospitalisation: An analysis from the phase 3 randomised Alpharadin in Symptomatic Prostate Cancer Patients (ALSYMPCA) trial. Eur J Cancer 2017;71:1-6.
86. Vogelzang NJ, Coleman RE, Michalski JM, et al. Hematologic Safety of Radium-223 Dichloride: Baseline Prognostic Factors Associated With Myelosuppression in the ALSYMPCA Trial. Clin Genitourin Cancer 2017;15:42-52.
87. Dan TD, Eldredge-Hindy HB, Hoffman-Censits J, et al. Hematologic Toxicity of Concurrent Administration of Radium-223 and Next-generation Antiandrogen Therapies. Am J Clin Oncol 2017;40:342-347.
88. Brauer A, Grubert LS, Roll W, et al. (177) Lu-PSMA-617 radioligand therapy and outcome in patients with metastasized castration-resistant prostate cancer. Eur J Nucl Med Mol Imaging 2017;44:1663-1670.
89. Sun M, Cole AP, Hanna N, Mucci LA, et al. Cognitive Impairment in Men with Prostate Cancer Treated with Androgen Deprivation Therapy: A Systematic Review and Meta-Analysis. J Urol 2018;199:1417-1425.
90. Ahmadi H, Daneshmand S. Androgen deprivation therapy: evidencebased management of side effects. BJU Int 2013;111:543-548.
91. Mateo J, Carreira S, Sandhu S, Miranda S, et al. DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer. N Engl J Med 2015;373:1697-1708.
92. Beer TM, Kwon ED, Drake CG, Fizazi K, et al. Randomized, DoubleBlind, Phase III Trial of Ipilimumab Versus Placebo in Asymptomatic or Minimally Symptomatic Patients With Metastatic ChemotherapyNaive Castration-Resistant Prostate Cancer. J Clin Oncol 2017;35:40-47.

APA	TAVUKÇU H, Kaplan M (2021). Approach to Prostate Cancer Treatment in Elderly Patients with High Comorbidity. , 73 - 82. 10.4274/uob.galenos.2019.1455
Chicago	TAVUKÇU HASAN HÜSEYİN,Kaplan Mustafa Approach to Prostate Cancer Treatment in Elderly Patients with High Comorbidity. (2021): 73 - 82. 10.4274/uob.galenos.2019.1455
MLA	TAVUKÇU HASAN HÜSEYİN,Kaplan Mustafa Approach to Prostate Cancer Treatment in Elderly Patients with High Comorbidity. , 2021, ss.73 - 82. 10.4274/uob.galenos.2019.1455
AMA	TAVUKÇU H,Kaplan M Approach to Prostate Cancer Treatment in Elderly Patients with High Comorbidity. . 2021; 73 - 82. 10.4274/uob.galenos.2019.1455
Vancouver	TAVUKÇU H,Kaplan M Approach to Prostate Cancer Treatment in Elderly Patients with High Comorbidity. . 2021; 73 - 82. 10.4274/uob.galenos.2019.1455
IEEE	TAVUKÇU H,Kaplan M "Approach to Prostate Cancer Treatment in Elderly Patients with High Comorbidity." , ss.73 - 82, 2021. 10.4274/uob.galenos.2019.1455
ISNAD	TAVUKÇU, HASAN HÜSEYİN - Kaplan, Mustafa. "Approach to Prostate Cancer Treatment in Elderly Patients with High Comorbidity". (2021), 73-82. https://doi.org/10.4274/uob.galenos.2019.1455

APA	TAVUKÇU H, Kaplan M (2021). Approach to Prostate Cancer Treatment in Elderly Patients with High Comorbidity. Üroonkoloji Bülteni, 20(2), 73 - 82. 10.4274/uob.galenos.2019.1455
Chicago	TAVUKÇU HASAN HÜSEYİN,Kaplan Mustafa Approach to Prostate Cancer Treatment in Elderly Patients with High Comorbidity. Üroonkoloji Bülteni 20, no.2 (2021): 73 - 82. 10.4274/uob.galenos.2019.1455
MLA	TAVUKÇU HASAN HÜSEYİN,Kaplan Mustafa Approach to Prostate Cancer Treatment in Elderly Patients with High Comorbidity. Üroonkoloji Bülteni, vol.20, no.2, 2021, ss.73 - 82. 10.4274/uob.galenos.2019.1455
AMA	TAVUKÇU H,Kaplan M Approach to Prostate Cancer Treatment in Elderly Patients with High Comorbidity. Üroonkoloji Bülteni. 2021; 20(2): 73 - 82. 10.4274/uob.galenos.2019.1455
Vancouver	TAVUKÇU H,Kaplan M Approach to Prostate Cancer Treatment in Elderly Patients with High Comorbidity. Üroonkoloji Bülteni. 2021; 20(2): 73 - 82. 10.4274/uob.galenos.2019.1455
IEEE	TAVUKÇU H,Kaplan M "Approach to Prostate Cancer Treatment in Elderly Patients with High Comorbidity." Üroonkoloji Bülteni, 20, ss.73 - 82, 2021. 10.4274/uob.galenos.2019.1455
ISNAD	TAVUKÇU, HASAN HÜSEYİN - Kaplan, Mustafa. "Approach to Prostate Cancer Treatment in Elderly Patients with High Comorbidity". Üroonkoloji Bülteni 20/2 (2021), 73-82. https://doi.org/10.4274/uob.galenos.2019.1455